Lipella Pharmaceuticals Inc.
LIPO
$2.36
-$0.345-12.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -25.50% | 116.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -25.50% | 116.04% | |||
| Cost of Revenue | -6.48% | 1.49% | |||
| Gross Profit | 2.77% | 8.03% | |||
| SG&A Expenses | -17.58% | 14.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.33% | 5.53% | |||
| Operating Income | 8.51% | 0.56% | |||
| Income Before Tax | 9.38% | 0.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.38% | 0.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.38% | 0.20% | |||
| EBIT | 8.51% | 0.56% | |||
| EBITDA | 8.51% | 0.56% | |||
| EPS Basic | 46.69% | 7.70% | |||
| Normalized Basic EPS | 46.69% | 7.70% | |||
| EPS Diluted | 46.29% | 7.70% | |||
| Normalized Diluted EPS | 46.69% | 7.70% | |||
| Average Basic Shares Outstanding | 69.98% | 8.12% | |||
| Average Diluted Shares Outstanding | 69.98% | 8.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||